BridgeBio reported third-quarter revenue of $120.7 million, fueled by $108.1 million in U.S. net product sales of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, and disclosed two registrational wins that set up a 2026 filing wave: positive topline interim results from FORTIFY for bbp-418 in LGMD2i/R9 and positive topline results from CALIBRATE for encaleret in ADH1. As of October 25, 5,259 unique patient prescriptions for Attruby had been written by 1,355 prescribers since the U.S. approval in November 2024. The company ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities, alongside royalty-backed financing and new notes that extend its commercialization runway.
The strategic question is whether BridgeBio can leverage a rare-disease launch playbook across multiple genetic conditions fast enough to achieve scale before competition and capital costs compress the window. Attruby is already approved in the U.S., EU, Japan, and the UK, with ex-U.S. royalty revenue beginning to contribute. Clinically, the product differentiates on early outcomes: newly published ATTRIBUTE-CM data show reductions in cumulative cardiovascular events within the first month of treatment, with a 49% hazard reduction in cardiovascular death or recurrent hospitalization by month 30, and additional long-term analyses suggest sustained cardiovascular mortality benefit through 42 months. For payers and cardiologists, the immediacy and durability of benefit are meaningful, particularly as treatment-naïve uptake accelerates and physicians move stabilization earlier in the disease course.
The pipeline updates matter because they target first-approval opportunities in underserved genetic diseases and could diversify revenue beyond cardiology. In LGMD2i/R9, bbp-418 delivered a 1.8x increase in glycosylated alpha-dystroglycan at three months sustained to 12 months, an 82% reduction in serum CK, and clinically meaningful gains in ambulation and pulmonary function at 12 months versus placebo. An NDA is planned for the first half of 2026, positioning bbp-418 to become the first approved therapy for any form of LGMD, if successful. In ADH1, encaleret achieved the primary endpoint with 76% of participants reaching serum and urine calcium targets versus 4% on conventional therapy and restored parathyroid hormone in 91% at week 24. An NDA submission is also planned for the first half of 2026, with registrational programs in pediatric ADH1 and chronic hypoparathyroidism slated for 2026.
Commercial leaders should note the implications for patient-finding, evidence generation, and access. ATTR-CM diagnosis still lags prevalence; scaling echo- and scintigraphy-based detection and ensuring referral pathways will be decisive in sustaining growth against entrenched tafamidis. For LGMD2i/R9 and ADH1, Medical Affairs will need to educate on novel endpoints and natural history, build real-world evidence to support long-term functional benefit, and shape coverage criteria in small, genetically defined populations. Payers will scrutinize durability, quality-of-life impact, and total cost offsets, particularly as BridgeBio expands into pediatrics and chronic settings where lifetime exposure and monitoring raise budget and adherence questions.
The competitive context is tightening. In ATTR, stabilization and silencing modalities are converging while gene-editing programs advance, raising the bar for long-term disease modification. In achondroplasia, where infigratinib’s Phase 3 readout is expected in early 2026, BioMarin’s established therapy and emerging entrants set a high commercial and evidentiary threshold. Meanwhile, BridgeBio’s SG&A expansion and noncash interest from royalty obligations underscore a familiar rare-disease trade-off: front-loaded investment and structured capital in exchange for speed.
The next 12–18 months will test whether BridgeBio can convert early Attruby momentum and two near-term NDA shots into a durable, multi-asset rare-disease franchise. The decisive factor may be less about additional positive p-values and more about operational throughput: can the company industrialize patient identification, payer activation, and RWE at a pace that outstrips both incumbent defenses and the arrival of next-generation genetic therapies?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
